Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on...
Gespeichert in:
Veröffentlicht in: | Journal of thoracic oncology 2012-12, Vol.7 (12), p.1872-1876 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1876 |
---|---|
container_issue | 12 |
container_start_page | 1872 |
container_title | Journal of thoracic oncology |
container_volume | 7 |
creator | Matsubara, Daisuke Kanai, Yoshihiko Ishikawa, Shumpei Ohara, Shiori Yoshimoto, Taichiro Sakatani, Takashi Oguni, Sachiko Tamura, Tomoko Kataoka, Hiroaki Endo, Shunsuke Murakami, Yoshinori Aburatani, Hiroyuki Fukayama, Masashi Niki, Toshiro |
description | Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors. |
doi_str_mv | 10.1097/JTO.0b013e3182721ed1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273246879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086415331737</els_id><sourcerecordid>1273246879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQQC1ERUvhHyDkIwfSjj-TXJCq0NJWkSpVC1fLsSesIYlLnFDx7_FqF5A49DCakTVvZvwIecPgjEFdnt9u7s6gAyZQsIqXnKFnz8gJU0oXTFTw_FBDpeUxeZnSNwCpQFYvyDEXTEml4YR8ufE4LaEPzi4hTjT2tGk-Nrq4v9zQqzXt3sJEly3S63W0E23X6Su9yFB0dnZhiqOlDQ4DbcOE72nbFPzc-lfkqLdDwteHfEo-X11umuuivft001y0hVOshkK4zvaVBmCl70urpfMIveSutp0ufZk_x4UCV_NSiLpzQte8886rTmrlpRWn5N1-7sMcf6yYFjOG5PI5dsK4JsMyyKWuyjq3yn2rm2NKM_bmYQ6jnX8ZBmZn1GSj5n-jGXt72LB2I_q_0B-F_-Y-xmHBOX0f1keczRbtsGwNMC5FVcuC54pxAChy8B32YY9h1vMzZCK5gJNDH2Z0i_ExPH3Yb5jbk7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273246879</pqid></control><display><type>article</type><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</creator><creatorcontrib>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</creatorcontrib><description>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</description><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1097/JTO.0b013e3182721ed1</identifier><identifier>PMID: 23154560</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Animals ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Blotting, Western ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Cell line ; Cell Proliferation - drug effects ; Cytoskeletal Proteins - genetics ; Female ; Gefitinib ; Humans ; Immunoenzyme Techniques ; Lung adenocarcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Oncogene Proteins, Fusion - genetics ; Phosphorylation - drug effects ; Piperidines - administration & dosage ; Proto-Oncogene Proteins c-ret - genetics ; Quinazolines - administration & dosage ; Real-Time Polymerase Chain Reaction ; RET fusion ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; Transplantation, Heterologous ; Tumor Cells, Cultured ; Vandetanib</subject><ispartof>Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1872-1876</ispartof><rights>2012 International Association for the Study of Lung Cancer</rights><rights>2012International Association for the Study of Lung Cancer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</citedby><cites>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23154560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsubara, Daisuke</creatorcontrib><creatorcontrib>Kanai, Yoshihiko</creatorcontrib><creatorcontrib>Ishikawa, Shumpei</creatorcontrib><creatorcontrib>Ohara, Shiori</creatorcontrib><creatorcontrib>Yoshimoto, Taichiro</creatorcontrib><creatorcontrib>Sakatani, Takashi</creatorcontrib><creatorcontrib>Oguni, Sachiko</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kataoka, Hiroaki</creatorcontrib><creatorcontrib>Endo, Shunsuke</creatorcontrib><creatorcontrib>Murakami, Yoshinori</creatorcontrib><creatorcontrib>Aburatani, Hiroyuki</creatorcontrib><creatorcontrib>Fukayama, Masashi</creatorcontrib><creatorcontrib>Niki, Toshiro</creatorcontrib><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><description>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Blotting, Western</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cell line</subject><subject>Cell Proliferation - drug effects</subject><subject>Cytoskeletal Proteins - genetics</subject><subject>Female</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Lung adenocarcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Phosphorylation - drug effects</subject><subject>Piperidines - administration & dosage</subject><subject>Proto-Oncogene Proteins c-ret - genetics</subject><subject>Quinazolines - administration & dosage</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>RET fusion</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Transplantation, Heterologous</subject><subject>Tumor Cells, Cultured</subject><subject>Vandetanib</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQQC1ERUvhHyDkIwfSjj-TXJCq0NJWkSpVC1fLsSesIYlLnFDx7_FqF5A49DCakTVvZvwIecPgjEFdnt9u7s6gAyZQsIqXnKFnz8gJU0oXTFTw_FBDpeUxeZnSNwCpQFYvyDEXTEml4YR8ufE4LaEPzi4hTjT2tGk-Nrq4v9zQqzXt3sJEly3S63W0E23X6Su9yFB0dnZhiqOlDQ4DbcOE72nbFPzc-lfkqLdDwteHfEo-X11umuuivft001y0hVOshkK4zvaVBmCl70urpfMIveSutp0ufZk_x4UCV_NSiLpzQte8886rTmrlpRWn5N1-7sMcf6yYFjOG5PI5dsK4JsMyyKWuyjq3yn2rm2NKM_bmYQ6jnX8ZBmZn1GSj5n-jGXt72LB2I_q_0B-F_-Y-xmHBOX0f1keczRbtsGwNMC5FVcuC54pxAChy8B32YY9h1vMzZCK5gJNDH2Z0i_ExPH3Yb5jbk7c</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Matsubara, Daisuke</creator><creator>Kanai, Yoshihiko</creator><creator>Ishikawa, Shumpei</creator><creator>Ohara, Shiori</creator><creator>Yoshimoto, Taichiro</creator><creator>Sakatani, Takashi</creator><creator>Oguni, Sachiko</creator><creator>Tamura, Tomoko</creator><creator>Kataoka, Hiroaki</creator><creator>Endo, Shunsuke</creator><creator>Murakami, Yoshinori</creator><creator>Aburatani, Hiroyuki</creator><creator>Fukayama, Masashi</creator><creator>Niki, Toshiro</creator><general>Elsevier Inc</general><general>International Association for the Study of Lung Cancer</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201212</creationdate><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><author>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Blotting, Western</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cell line</topic><topic>Cell Proliferation - drug effects</topic><topic>Cytoskeletal Proteins - genetics</topic><topic>Female</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Lung adenocarcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Phosphorylation - drug effects</topic><topic>Piperidines - administration & dosage</topic><topic>Proto-Oncogene Proteins c-ret - genetics</topic><topic>Quinazolines - administration & dosage</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>RET fusion</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Transplantation, Heterologous</topic><topic>Tumor Cells, Cultured</topic><topic>Vandetanib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsubara, Daisuke</creatorcontrib><creatorcontrib>Kanai, Yoshihiko</creatorcontrib><creatorcontrib>Ishikawa, Shumpei</creatorcontrib><creatorcontrib>Ohara, Shiori</creatorcontrib><creatorcontrib>Yoshimoto, Taichiro</creatorcontrib><creatorcontrib>Sakatani, Takashi</creatorcontrib><creatorcontrib>Oguni, Sachiko</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kataoka, Hiroaki</creatorcontrib><creatorcontrib>Endo, Shunsuke</creatorcontrib><creatorcontrib>Murakami, Yoshinori</creatorcontrib><creatorcontrib>Aburatani, Hiroyuki</creatorcontrib><creatorcontrib>Fukayama, Masashi</creatorcontrib><creatorcontrib>Niki, Toshiro</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsubara, Daisuke</au><au>Kanai, Yoshihiko</au><au>Ishikawa, Shumpei</au><au>Ohara, Shiori</au><au>Yoshimoto, Taichiro</au><au>Sakatani, Takashi</au><au>Oguni, Sachiko</au><au>Tamura, Tomoko</au><au>Kataoka, Hiroaki</au><au>Endo, Shunsuke</au><au>Murakami, Yoshinori</au><au>Aburatani, Hiroyuki</au><au>Fukayama, Masashi</au><au>Niki, Toshiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2012-12</date><risdate>2012</risdate><volume>7</volume><issue>12</issue><spage>1872</spage><epage>1876</epage><pages>1872-1876</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><abstract>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23154560</pmid><doi>10.1097/JTO.0b013e3182721ed1</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1556-0864 |
ispartof | Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1872-1876 |
issn | 1556-0864 1556-1380 |
language | eng |
recordid | cdi_proquest_miscellaneous_1273246879 |
source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Blotting, Western Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell line Cell Proliferation - drug effects Cytoskeletal Proteins - genetics Female Gefitinib Humans Immunoenzyme Techniques Lung adenocarcinoma Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mice Mice, Inbred NOD Mice, SCID Oncogene Proteins, Fusion - genetics Phosphorylation - drug effects Piperidines - administration & dosage Proto-Oncogene Proteins c-ret - genetics Quinazolines - administration & dosage Real-Time Polymerase Chain Reaction RET fusion Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics Transplantation, Heterologous Tumor Cells, Cultured Vandetanib |
title | Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20CCDC6-RET%20Fusion%20in%20the%20Human%20Lung%20Adenocarcinoma%20Cell%20Line,%20LC-2/ad&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Matsubara,%20Daisuke&rft.date=2012-12&rft.volume=7&rft.issue=12&rft.spage=1872&rft.epage=1876&rft.pages=1872-1876&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1097/JTO.0b013e3182721ed1&rft_dat=%3Cproquest_cross%3E1273246879%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273246879&rft_id=info:pmid/23154560&rft_els_id=S1556086415331737&rfr_iscdi=true |